Biolex Inc. has established a development advisory board that includes a blue ribbon group of experts in protein manufacturing, process development, and clinical and regulatory areas.

A venture-backed company, Biolex uses the aquatic Lemna plant to make proteins for drug use. The company currently has top-tier corporate collaborations with pharmaceutical companies such as Bayer Corp., Centocor Inc. and Debiopharm and an unnamed major pharmaceutical company to make seven different proteins.

Biolex says it formed the advisory board to help it move its pipeline products from research into development.

The five people appointed to the development advisory board are:

  • Carl E. Brooks who has held the positions of President and CEO of Cryopharm Corp and President of the Hyland Division of Baxter International, a fully integrated therapeutic protein business. He is a member of the Board of Directors for Inhibitex, Quantumcor and Bluebird Biosciences.

  • Richard V. McCloskey, M.D., vice-president of medical research at Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson. Previously, Dr. McCloskey held a series of senior clinical positions at Centocor, Hoffmann La Roche and academia.

  • James E. Pennington, M.D.. executive vice president of medical and scientific affairs at InterMune, Inc. Previously, Dr. Pennington held senior clinical positions at Alpha Therapeutics, Shamen Pharmaceuticals,Bayer and academia.

  • Kathryn E. Stein, Ph.D., vice president for product development and regulatory affairs at MacroGenics. From 1980 to 2002, Dr. Stein was a member of the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Admistration, and director of the division of monoclonal antibodies from its inception in 1992 until her departure from the FDA in 2002. She was also the key framer of the FDA Guidance document on therapeutic proteins made from transgenic plant systems.

  • Mark F. Witcher, Ph.D., has held the positions of Vice President of manufacturing for MERIX Bioscience, senior vice president of manufacturing operations for Covance Biotechnology Services (now Diosynth RTP), and vice president of manufacturing at Amgen Inc.

Biolex, Inc. is a biopharmaceutical company devoted to discovering, developing and commercializing its proprietary advanced protein expression technology for the development of human therapeutics.

Biolex
(repeat the www link)